STUDY OF FIBROSIS PATHWAYS (TGF-Β AND WNT SIGNALING) AS THERAPEUTIC TARGETS IN CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.7492/6nvwdg38Keywords:
Chronic kidney disease, renal fibrosis, TGF-β signaling, Wnt/β-catenin pathway, therapeutic targetsAbstract
Chronic kidney disease (CKD) is a progressive disorder, which is related to irreversible renal failure, to a large degree, facilitated by renal
fibrosis. Fibrosis refers to the excess deposition of an extracellular matrix (ECM) that damages the structure and deteriorates the functionality.
The transforming growth factor-beta (TGF- 1) and Wnt/ -catenin signaling networks are among the major molecular mediators of epithelialto-mesenchymal transition (EMT), inflammation and fibroblast stimulation of renal fibrosis. This review discusses molecular pathways of
TGF-B and Wnt in CKD, cross-talk, and new treatment approaches of these pathways. Recent developments emphasize pharmacological
inhibitors, natural products and traditional medicine methods that regulate such signaling cascades. Moreover, the idea of individual antifibrotic
treatment is becoming more popular, which will have to personalize treatment according to the molecular profiles. The knowledge of these
pathways provides good opportunities to decelerate or halt fibrosis of the kidneys and enhance the results of CKD.
